Search results
Results from the Think 24/7 Content Network
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled ...
This class of drugs are mimics of serotonin that activate 5-HT receptor subtypes that release norepinephrine and dopamine. 2C-B-BZP. 3-Chlorophenylpiperazine, meta-Chlorophenylpiperazine, mCPP. 4-Fluorophenylpiperazine, para-Fluorophenylpiperazine, pFPP, 4-FPP, Fluoperazine, Flipiperazine.
2-Aminoindane ( 2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug. [1] It acts as a selective substrate for NET and DAT. [2] [3]
MDMAI. 5,6-Methylenedioxy-N-methyl-2-aminoindane ( MDMAI ), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in animals and a putative entactogen in humans. [1]
The substituted methylenedioxyphenethylamines (abbreviated as MDxx) represent a diverse chemical class of compounds derived from phenethylamines. This category encompasses numerous psychoactive substances with entactogenic, psychedelic, and/or stimulant properties, in addition to entheogens. These compounds find application as research ...
Infobox references. 2C-D ( 2,5-dimethoxy-4-methylphenethylamine or 2C-M) is a psychedelic drug of the 2C family that is sometimes used as an entheogen. It was first synthesized in 1970 by a team from the Texas Research Institute of Mental Sciences, [ 1] and its activity was subsequently investigated in humans by Alexander Shulgin.
A serotonin–norepinephrine–dopamine releasing agent ( SNDRA ), also known as a triple releasing agent ( TRA ), is a type of drug which induces the release of serotonin, norepinephrine / epinephrine, and dopamine in the brain and body. SNDRAs produce euphoriant, entactogen, and psychostimulant effects, and are almost exclusively encountered ...